Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
7.7 USD | +1.18% | -5.64% | -12.20% |
Mar. 27 | MiMedx Group Says FDA Affirms Axiofill Falls Short of Regulatory Standards for Tissue-Based Products | MT |
Mar. 27 | MiMedx Says FDA Still Won't Budge on Axiofill Designation, Files Lawsuit | DJ |
Financials (USD)
Sales 2024 * | 357M | Sales 2025 * | 403M | Capitalization | 1.13B |
---|---|---|---|---|---|
Net income 2024 * | 43M | Net income 2025 * | 56M | EV / Sales 2024 * | 3.17 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.81 x |
P/E ratio 2024 * |
25
x | P/E ratio 2025 * |
19.7
x | Employees | 895 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.1% |
Latest transcript on MiMedx Group, Inc.
1 day | +1.18% | ||
1 week | -5.64% | ||
Current month | -5.64% | ||
1 month | -6.10% | ||
3 months | -13.48% | ||
6 months | +1.58% | ||
Current year | -12.20% |
Managers | Title | Age | Since |
---|---|---|---|
Joe Capper
CEO | Chief Executive Officer | 60 | 23-01-26 |
Douglas Rice
DFI | Director of Finance/CFO | 58 | 23-07-04 |
John R. Harper
CTO | Chief Tech/Sci/R&D Officer | - | 21-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
William Hawkins
BRD | Director/Board Member | 70 | 20-07-01 |
Phyllis Gardner
BRD | Director/Board Member | 73 | 21-03-07 |
K. Newton
BRD | Director/Board Member | 61 | 19-06-18 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.05% | 2 M€ | -.--% | ||
0.01% | 735 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 7.7 | +1.18% | 943,504 |
24-03-27 | 7.61 | -0.13% | 1,821,742 |
24-03-26 | 7.62 | -2.68% | 739,261 |
24-03-25 | 7.83 | -2.61% | 746,715 |
24-03-22 | 8.04 | -1.47% | 576,860 |
Delayed Quote Nasdaq, March 28, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.20% | 1.13B | |
+9.23% | 1.07B | |
-8.55% | 150M | |
+28.14% | 68.16M | |
+13.27% | 62.25M | |
-16.28% | 61.27M | |
+2.98% | 59.64M |